Susquehanna Fundamental Investments LLC Invests $18.71 Million in Insmed Incorporated (NASDAQ:INSM)

Susquehanna Fundamental Investments LLC bought a new position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 270,960 shares of the biopharmaceutical company's stock, valued at approximately $18,707,000. Susquehanna Fundamental Investments LLC owned about 0.15% of Insmed at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after acquiring an additional 1,075,796 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Insmed by 1.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock valued at $877,113,000 after purchasing an additional 123,429 shares during the period. Capital International Investors increased its holdings in shares of Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after purchasing an additional 593,206 shares during the period. Geode Capital Management LLC grew its holdings in Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after acquiring an additional 273,759 shares during the period. Finally, Artisan Partners Limited Partnership grew its holdings in Insmed by 8.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock worth $215,842,000 after acquiring an additional 242,242 shares during the period.

Insider Buying and Selling at Insmed

In other news, CFO Sara Bonstein sold 28,390 shares of Insmed stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,296,751.00. Following the completion of the transaction, the chief financial officer now directly owns 155,506 shares in the company, valued at approximately $12,580,435.40. The trade was a 15.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00. Following the transaction, the chief executive officer now owns 379,534 shares of the company's stock, valued at approximately $29,580,879.96. The trade was a 4.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 380,657 shares of company stock valued at $30,330,039. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Performance

Shares of Insmed stock traded up $0.52 during trading on Thursday, reaching $72.52. The company's stock had a trading volume of 910,767 shares, compared to its average volume of 2,303,275. The firm has a market cap of $13.19 billion, a PE ratio of -12.98 and a beta of 1.07. The business's 50-day moving average price is $73.67 and its 200-day moving average price is $73.51. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent research reports. Truist Financial upped their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research report on Friday, February 21st. UBS Group boosted their price objective on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. HC Wainwright restated a "buy" rating and set a $90.00 price target on shares of Insmed in a research report on Tuesday, April 22nd. Finally, Bank of America boosted their target price on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and an average price target of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.